Victory Capital Management Inc. Purchases 215,874 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Victory Capital Management Inc. grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 43.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 710,688 shares of the specialty pharmaceutical company's stock after acquiring an additional 215,874 shares during the period. Victory Capital Management Inc. owned about 2.21% of Collegium Pharmaceutical worth $27,461,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gladius Capital Management LP acquired a new position in Collegium Pharmaceutical during the second quarter valued at $32,000. nVerses Capital LLC lifted its position in Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,600 shares during the period. GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 792 shares during the period. CWM LLC raised its position in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after buying an additional 736 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth about $204,000.

Collegium Pharmaceutical Stock Performance

COLL stock traded down $0.36 during midday trading on Monday, reaching $29.22. The stock had a trading volume of 562,031 shares, compared to its average volume of 445,685. The stock has a market cap of $942.35 million, a PE ratio of 12.65 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 52-week low of $25.13 and a 52-week high of $42.29. The firm has a fifty day simple moving average of $36.36 and a two-hundred day simple moving average of $35.00. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. HC Wainwright increased their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, September 5th. Finally, Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $42.60.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.